Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of weekly paclitaxel versus olaparib versus olaparib + cediranib in relapsed ovarian cancer
ISRCTN14784018Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Mar 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Weekly paclitaxel, Olaparib and Olaparib + cediranib (3 arms). Primary endpoint: Progression-free survival. Started Mar 2017; status: completed.
02
Drugs
paclitaxelolaparibcediranib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ISRCTN14784018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14784018.